Want to see OTLC full AI Analyst Report?
OTLC Stock Chart & Stats
$0.04
<$0.01(19.29%)
At close: 4:00 PM EDT
$0.04
<$0.01(19.29%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume458.46K
Average Volume (3M)410.07K
Market Cap
$15.16M
Enterprise Value$31.21
Total Cash (Recent Filing)$63.61B
Total Debt (Recent Filing)$16.79T
Price to Earnings (P/E)<0.1
Beta-0.14
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.58
Shares Outstanding443,615,720
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported LeverageReported debt-to-equity near 0.06 indicates modest leverage, which reduces near-term solvency and interest-burden risk. This durable balance-sheet characteristic gives the company more flexibility to manage short-term obligations and negotiate financing without immediate distress, aiding operational continuity.
Strategic IP Stake And LicenseThe Lunai preferred stake and perpetual, broad IP license create a non-cash strategic asset base that strengthens long-term technology access. This can enable collaborations, royalties, or licensing deals, providing optionality and potential non-dilutive value capture distinct from short-term funding cycles.
Management Incentives Tied To UplistingPerformance-based RSUs align executive and board incentives with achieving an uplisting and improved capital markets access. This alignment can reduce agency friction, focus management on governance, reporting and operational milestones needed for sustained access to broader institutional capital over the medium term.
Bears Say
Minimal Revenue And Persistent LossesNear-zero recurring revenue and sustained operating losses indicate lack of commercial traction and no scalable revenue base. Over a multi-month horizon this undermines self-sustainability, limits reinvestment capacity, and means value depends primarily on R&D outcomes rather than stable cash generation.
Structurally Negative Cash FlowConsistent negative operating and free cash flows show the business cannot self-fund operations or development. This structural cash burn requires recurring external financing, increasing dilution risk and constraining long-term R&D planning, hiring, and clinical advancement without new capital.
Dependence On Dilutive Convertible FinancingFrequent use of short-dated, equity-linked convertible notes with discounts and commitment shares evidences dependence on dilutive private capital. Such financing protects lenders and accelerates dilution upon conversion, raising long-term capital structure risk and potentially impairing existing shareholder value.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $15.16M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 12 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Currently, no data Available
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 443,615,720 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.